Drug testing in the workplace

Hieu M. Phan, Keith Yoshizuka, Daryl J. Murry, Paul J. Perry

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Congress passed the Drug-Free Workplace Act in April 1988, which resulted in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. The intent was to establish a substance-free work environment for all federal workers by requiring that all federal employees pass a urine drug test before employment. These guidelines specifically, and exclusively, focus on testing urine specimens for metabolites of marijuana, cocaine, phencyclidine, opiates (focusing on heroin metabolites), and amphetamines (including Ecstasy). Since then, there have been many scientific, technical, and legal challenges to the validity of urine drug testing. In response, the Substance Abuse and Mental Health Services Administration, a division operating under the executive branch of the United States Department of Health and Human Services, put forth, through many revisions, strict procedural guidelines and specimen validity-testing criteria to manage suspicious or adulterated samples during and after urine collection. This review focuses on the legal ramifications, the procedural process, and the sensitivity and specificity of the two urine drug tests used for workplace drug testing: immunoassay and gas chromatography-mass spectrometry. Moreover, we dissect the problematic issue of cross-sensitivity between illicit and prescription drugs, and how this affects the validity of future urine drug testing.

Original languageEnglish (US)
Pages (from-to)649-656
Number of pages8
JournalPharmacotherapy
Volume32
Issue number7
DOIs
StatePublished - Jul 1 2012

Fingerprint

Workplace
Urine
Pharmaceutical Preparations
Guidelines
Opiate Alkaloids
Health Services Misuse
Health Services Administration
United States Dept. of Health and Human Services
Amphetamines
Phencyclidine
Urine Specimen Collection
Prescription Drugs
Heroin
Mental Health Services
Street Drugs
Cannabis
Cocaine
Immunoassay
Gas Chromatography-Mass Spectrometry
Substance-Related Disorders

Keywords

  • Confirmation assay
  • Forensic drug testing
  • Immunoassay screening
  • Specimen validity testing
  • Urine drug testing
  • Workplace drug testing

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Phan, H. M., Yoshizuka, K., Murry, D. J., & Perry, P. J. (2012). Drug testing in the workplace. Pharmacotherapy, 32(7), 649-656. https://doi.org/10.1002/j.1875-9114.2011.01089.x

Drug testing in the workplace. / Phan, Hieu M.; Yoshizuka, Keith; Murry, Daryl J.; Perry, Paul J.

In: Pharmacotherapy, Vol. 32, No. 7, 01.07.2012, p. 649-656.

Research output: Contribution to journalReview article

Phan, HM, Yoshizuka, K, Murry, DJ & Perry, PJ 2012, 'Drug testing in the workplace', Pharmacotherapy, vol. 32, no. 7, pp. 649-656. https://doi.org/10.1002/j.1875-9114.2011.01089.x
Phan, Hieu M. ; Yoshizuka, Keith ; Murry, Daryl J. ; Perry, Paul J. / Drug testing in the workplace. In: Pharmacotherapy. 2012 ; Vol. 32, No. 7. pp. 649-656.
@article{9e9d366765394c35ad02a8e991039641,
title = "Drug testing in the workplace",
abstract = "Congress passed the Drug-Free Workplace Act in April 1988, which resulted in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. The intent was to establish a substance-free work environment for all federal workers by requiring that all federal employees pass a urine drug test before employment. These guidelines specifically, and exclusively, focus on testing urine specimens for metabolites of marijuana, cocaine, phencyclidine, opiates (focusing on heroin metabolites), and amphetamines (including Ecstasy). Since then, there have been many scientific, technical, and legal challenges to the validity of urine drug testing. In response, the Substance Abuse and Mental Health Services Administration, a division operating under the executive branch of the United States Department of Health and Human Services, put forth, through many revisions, strict procedural guidelines and specimen validity-testing criteria to manage suspicious or adulterated samples during and after urine collection. This review focuses on the legal ramifications, the procedural process, and the sensitivity and specificity of the two urine drug tests used for workplace drug testing: immunoassay and gas chromatography-mass spectrometry. Moreover, we dissect the problematic issue of cross-sensitivity between illicit and prescription drugs, and how this affects the validity of future urine drug testing.",
keywords = "Confirmation assay, Forensic drug testing, Immunoassay screening, Specimen validity testing, Urine drug testing, Workplace drug testing",
author = "Phan, {Hieu M.} and Keith Yoshizuka and Murry, {Daryl J.} and Perry, {Paul J.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1002/j.1875-9114.2011.01089.x",
language = "English (US)",
volume = "32",
pages = "649--656",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "7",

}

TY - JOUR

T1 - Drug testing in the workplace

AU - Phan, Hieu M.

AU - Yoshizuka, Keith

AU - Murry, Daryl J.

AU - Perry, Paul J.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Congress passed the Drug-Free Workplace Act in April 1988, which resulted in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. The intent was to establish a substance-free work environment for all federal workers by requiring that all federal employees pass a urine drug test before employment. These guidelines specifically, and exclusively, focus on testing urine specimens for metabolites of marijuana, cocaine, phencyclidine, opiates (focusing on heroin metabolites), and amphetamines (including Ecstasy). Since then, there have been many scientific, technical, and legal challenges to the validity of urine drug testing. In response, the Substance Abuse and Mental Health Services Administration, a division operating under the executive branch of the United States Department of Health and Human Services, put forth, through many revisions, strict procedural guidelines and specimen validity-testing criteria to manage suspicious or adulterated samples during and after urine collection. This review focuses on the legal ramifications, the procedural process, and the sensitivity and specificity of the two urine drug tests used for workplace drug testing: immunoassay and gas chromatography-mass spectrometry. Moreover, we dissect the problematic issue of cross-sensitivity between illicit and prescription drugs, and how this affects the validity of future urine drug testing.

AB - Congress passed the Drug-Free Workplace Act in April 1988, which resulted in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. The intent was to establish a substance-free work environment for all federal workers by requiring that all federal employees pass a urine drug test before employment. These guidelines specifically, and exclusively, focus on testing urine specimens for metabolites of marijuana, cocaine, phencyclidine, opiates (focusing on heroin metabolites), and amphetamines (including Ecstasy). Since then, there have been many scientific, technical, and legal challenges to the validity of urine drug testing. In response, the Substance Abuse and Mental Health Services Administration, a division operating under the executive branch of the United States Department of Health and Human Services, put forth, through many revisions, strict procedural guidelines and specimen validity-testing criteria to manage suspicious or adulterated samples during and after urine collection. This review focuses on the legal ramifications, the procedural process, and the sensitivity and specificity of the two urine drug tests used for workplace drug testing: immunoassay and gas chromatography-mass spectrometry. Moreover, we dissect the problematic issue of cross-sensitivity between illicit and prescription drugs, and how this affects the validity of future urine drug testing.

KW - Confirmation assay

KW - Forensic drug testing

KW - Immunoassay screening

KW - Specimen validity testing

KW - Urine drug testing

KW - Workplace drug testing

UR - http://www.scopus.com/inward/record.url?scp=84864621066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864621066&partnerID=8YFLogxK

U2 - 10.1002/j.1875-9114.2011.01089.x

DO - 10.1002/j.1875-9114.2011.01089.x

M3 - Review article

C2 - 22605533

AN - SCOPUS:84864621066

VL - 32

SP - 649

EP - 656

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 7

ER -